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Antibodies against peripheral 
nerve antigens in chronic 
inflammatory demyelinating 
polyradiculoneuropathy
Luis Querol1,2, Ana M Siles1,2, Roser Alba-Rovira  1,2, Agustín Jáuregui3, Jérôme Devaux4, 
Catherine Faivre-Sarrailh4, Josefa Araque1,2, Ricard Rojas-Garcia1,2, Jordi Diaz-Manera1,2, 
Elena Cortés-Vicente1,2, Gisela Nogales-Gadea5, Miquel Navas-Madroñal1,2, Eduard Gallardo  1,2 
& Isabel Illa1,2
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous disease in 
which diverse autoantibodies have been described but systematic screening has never been performed. 
Detection of CIDP-specific antibodies may be clinically useful. We developed a screening protocol to 
uncover novel reactivities in CIDP. Sixty-five CIDP patients and 28 controls were included in our study. 
Three patients (4.6%) had antibodies against neurofascin 155, four (6.2%) against contactin-1 and 
one (1.5%) against the contactin-1/contactin-associated protein-1 complex. Eleven (18.6%) patients 
showed anti-ganglioside antibodies, and one (1.6%) antibodies against peripheral myelin protein 
2. No antibodies against myelin protein zero, contactin-2/contactin-associated protein-2 complex, 
neuronal cell adhesion molecule, gliomedin or the voltage-gated sodium channel were detected. In 
IgG experiments, three patients (5.3%) showed a weak reactivity against motor neurons; 14 (24.6%) 
reacted against DRG neurons, four of them strongly (7.0%), and seven (12.3%) reacted against Schwann 
cells, three of them strongly (5.3%). In IgM experiments, six patients (10.7%) reacted against DRG 
neurons, while three (5.4%) reacted against Schwann cells. However, results were not statistically 
significant when compared to controls. Immunoprecipitation experiments identified CD9 and L1CAM 
as potential antigens, but reactivity could not be confirmed with cell-based assays. In summary, we 
describe a diverse autoantibody repertoire in CIDP patients, reinforcing the hypothesis of CIDP’s 
pathophysiological heterogeneity.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disabling disease with a pathogenesis 
that remains largely unknown1. CIDP response to immune therapies and scarce experimental evidence on passive 
transfer animal models suggest that humoral factors play a role in its pathogenesis2. CIDP diagnosis is based on 
clinical and electrophysiological criteria3 that allow the inclusion of a broad spectrum of patients within CIDP, 
including typical and atypical variants. This heterogeneity has hindered the description of disease-specific bio-
markers, despite intensive research efforts4.
The response of CIDP patients to intravenous immunoglobulin (IVIg) and plasma exchange (PlEx) suggests 
that humoral factors are involved in its pathogenesis. The search of autoantibodies has been the most important 
laboratory research topic in CIDP. Initial focus was placed on myelin antigens. Classical studies, using diverse 
techniques, detected higher frequencies of antibodies against myelin protein zero (MPZ), peripheral myelin pro-
tein 2 (PMP2) or peripheral myelin protein 22 (PMP22)5–10. However, meaningful clinical-immunological cor-
relations with those antigens were not established. CIDP patients harboring antibodies against LM1-containing 
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ganglioside complexes, present more frequently with ataxia, although these results await replication in inde-
pendent cohorts11,12. We and others have recently detected antibodies targeting node of Ranvier proteins such 
as gliomedin, neuronal cell adhesion molecule (NrCAM), neurofascin 140 (NF140), neurofascin 186 (NF186); 
and paranode of Ranvier; contactin-1 (CNTN1), contactin-associated protein 1 (CASPR1) and neurofascin 155 
(NF155)13–17. Our group described that patients harboring antibodies against CNTN1 and NF155 of the immu-
noglobulin G4 (IgG4) isotype present with specific clinical features15,18. Studies by other groups have validated 
these clinical-immunological correlations and refined the clinical phenotypes and paraclinical features associated 
to these autoantibodies19–23. In vitro and in vivo models of anti-CNTN1 IgG4 passive-transfer, demonstrate that 
anti-CNTN1 antibodies are pathogenic, strengthening the idea that CIDP is an autoantibody-mediated disease24.
Considering that CIDP-specific autoantibodies are not detected in the majority of CIDP patients we developed 
this study to: (1) systematically screen for immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibod-
ies against previously described antigens and peripheral nerve components, (2) identify the molecular targets of 
the immune response in those patients reacting against peripheral nerve components in which the target antigens 
were unknown and (3) to establish clinical-immunological correlations.
Results
Sixty-five patients fulfilling criteria for CIDP were identified and included in the study. Twenty-nine of them 
(29/65; 44.6%) were women (mean age 64.0 ± 17.3 years) while 36 of them (36/65; 55.4%) were men (mean age 
61.3 ± 15.3 years). Forty-four patients (67.7%) presented with a typical CIDP while 21 presented with an atypical 
CIDP (32.3%) (Supplementary Table S1).
Eleven patients (11/59; 18.6%) showed anti-ganglioside antibody reactivity by enzyme-linked immunosorbent 
assay (ELISA). Four of them (6.7%) showed high anti-GM1 IgM antibody titers (two of them with anti-GD1b 
IgM, with or without additional reactivities) (Table 1). Four patients reacted against CNTN1 (4/65; 6.2%), one 
against the CNTN1/CASPR1 complex (1/65; 1.5%) and three against NF155 (3/65; 4.6%). All of them except 
two (one CNTN1 and one NF155 positive) were previously described elsewhere15,18. Only one patient (1/62; 
1.6%) reacted against PMP2 (Fig. 1). CSF from this patient also showed IgG reactivity against PMP2-transfected 
human embryonic kidney (HEK) cells. None of our CIDP patients reacted against any of the other candidate 
antigens (MPZ, NrCAM, contactin-2 (CNTN2)/contactin-associated protein 2 (CASPR2) complex, gliome-
din and voltage-gated sodium channel subunits B1 (NavB1) and B2 (NavB2)). For further detailed results see 
Supplementary Table S2.
Immunocytochemistry (ICC) experiments with dorsal root ganglion (DRG) and motor neurons and Schwann 
cells (human undifferentiated Schwann cell line) were used to identify novel reactivities against neural compo-
nents. Patients with anti-CNTN1, anti-CNTN1/CASPR1, who show strong reactivity against any type of neuron, 
Patient ID Results
7
sulfatides IgM 1/31356
sulfatides IgG 1/832
22 IgM aGM1 1/500
24 sulfatides IgM 1/592
31
IgG GM1 1/6160
IgM GM1 1/2314
IgM aGM1 1/1442
IgM GD1b1/500
32 IgG aGM1 1/580
36 IgM GM1 1/2154
39
IgG aGM1 1/528
IgG GD1a 1/528
IgM aGM1 1/2559
sulfatides IgM 1/3245
sulfatides IgG 1/831
55
sulfatides IgM 1/800
IgM aGM1 1/500
56
IgG aGM1 1/1000
IgM GM1 1/500
64
IgM GM1 > 1/12500
IgM aGM1 > 1/12500
IgM GD1b > 1/12500
65
IgM GM1 1/7829
IgM aGM1 1/2359
IgM GD1b 1/2868
Table 1. CIDP patients harbouring anti-ganglioside antibodies. Fifty-nine patients were screened using our 
institution’s anti-ganglioside ELISA diagnostic technique, further confirmed by TLC.
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and anti-NF155 antibodies, who do not react against neurons, were excluded from these analyses. As a result, a 
maximum of 57 patients were screened for novel reactivities. During the course of our experiments we ran out of 
sera from one of the patients, leaving a total of 56 patients in IgM experiments.
In IgG experiments, three patients (3/57; 5.3%) showed only mild IgG staining in motor neuron ICC and 
therefore were not further used for immunoprecipitation (IP) experiments. Fourteen patients (14/57; 24.6%) 
presented with IgG reactivity against DRG neurons. Of those, only four (4/57; 7.0%) showed moderate to intense 
reactivity against DRG (Fig. 2A). Sera from three of these patients showing moderate or strong reactivity and a 
normal control were used to try to identify the target antigens using DRG neurons as the IP substrate. No relevant 
antigens were identified in comparison to the control serum. Finally, we used a commercial human undifferen-
tiated Schwann cell line to screen for antibodies against Schwann cells. Seven patients (7/57; 12.3%) showed IgG 
reactivity towards the human Schwann cell line, although only three (3/57; 5.3%) showed consistent moderate to 
high intensity staining (Fig. 2B). Interestingly, the only patient showing antibodies against PMP2 showed weak 
reactivity against human Schwann cells. Sera from these three patients strongly reacting against human Schwann 
cells and one control serum were used for IP experiments, but mass spectrometry analysis did not reveal any rele-
vant antigen in CIDP patients when compared to the control individual. Two patients with weak reactivity against 
Schwann cells also showed weak staining in DRG neurons ICC. Another patient, highly reactive against Schwann 
cells also showed weak reactivity against DRG neurons. No cross-reactivity was found between motor neurons 
and DRG neurons or Schwann cells (see Table 2). Additionally, statistical comparison between ICC results from 
patients and controls did not provide evidence of differentially relevant IgG staining in DRG neurons (p = 0.6793) 
or Schwann cells (p = 0.5476) (Table 3).
In IgM experiments, six patients (6/56; 10.7%) showed reactivity against DRG neurons, while three (3/56; 
5.4%) reacted against a human Schwann cell line. Only one patient (1/56; 1.8%) per each group presented with 
moderate (score two out of three) intensity IgM staining (Table 2). As with IgG experiments, no cross-reactivity 
was either appreciated between both cell types. IgM IP analysis were not performed in this study, due to the 
staining being exclusively moderate and poorly significant, as only one in 56 (1.8%) patients featured it in both 
cell types. As with IgG experiments, statistical comparison between IgM ICC results from patients and controls 
showed no statistically significant differences between both groups in DRG neurons (p = 0.2565) or Schwann 
cells (p = 1) (Table 3).
Figure 1. Positive PMP2 ICC. HEK293 cells were transfected with a mammalian expression vector encoding 
PMP2 with the use of Lipofectamine 2000 (Invitrogen, CA, USA) and ICC was performed as described in 
Supplementary Table S3. Patient’s 22 sera positivity can be appreciated in green, commercial antibody staining 
in red and a merged picture of both can be found above with nuclei stained in blue.
Figure 2. IgG positivity in DRG neurons and Schwann cells. Patients’ sera were tested by IgG and IgM ICC 
experiments with live DRG neurons and Schwann cells. Strong staining with the use of an anti-human IgG 
Alexa Fluor 488 antibody (Thermo Fisher Scientific, MA, USA) can be appreciated for DRG neurons (A) and 
Schwann cells (B).
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Whole nerve lysate from rat sciatic nerve and human cauda equina served as substrate for IP experiments 
with pooled sera from five typical CIDP cases. L1 cell adhesion molecule (L1CAM), a protein of the neurofascin 
family, was identified as a potential candidate antigen in the whole-nerve sciatic nerve lysate IP experiment but 
confirmatory ICC tests with L1CAM-transfected HEK cells did not confirm reactivity in any of the typical CIDP 
cases. Cluster of differentiation 9 (CD9), a protein of the tetraspanin family present in the paranode of Ranvier, 
was identified as a potential candidate antigen using human cauda equina as the substrate for IP studies with typ-
ical CIDP cases but, again, this was not confirmed in ICC experiments using CD9-transfected HEK cells.
No specific clinical features were associated with reactivity against each neural cell. The two patients with IgM 
antibodies against GM1 plus GD1b presented with an asymmetric sensory-motor onset in the upper limbs com-
patible with Lewis-Sumner CIDP variant, although later in the disease course progressed towards a bilateral, sym-
metric polyneuropathy. The other two patients with anti-GM1 antibodies presented with a typical CIDP variant. 
Interestingly, three of the anti-GM1 positive patients showed normal sensory nerve conductions despite severe 
sensory involvement, suggesting preganglionar damage. The fourth patient showed sensory-motor involvement 
in the EMG. Finally, the only patient reacting against PMP2 presented with a typical CIDP phenotype.
Discussion
Our study describes a comprehensive autoantibody screening approach to identify clinically relevant antigens 
in CIDP, and provides experimental evidence of the immunopathological diversity in patients fulfilling CIDP 
diagnostic criteria. A subset of seronegative CIDP patients reacted against neural structures and gangliosides. 
However, IP experiments in patients reacting against neural cells did not reveal novel antigens, and frequencies 
of reactivity against neural cells did not differ from normal controls. We did not identify patients harboring anti-
bodies against node/paranode of Ranvier proteins other than CNTN1 or NF155.
Aside from the inclusion of a few new CIDP patients in comparison to previous studies15,18, the novelty of our 
work relies on describing one new CNTN1 positive patient, one new NF155 positive patient, one patient positive 
for PMP2 and 11 CIDP patients with anti-ganglioside antibodies. Additionally, we have tested candidate antigens 
described in the bibliography and performed systematic antigen screening in rat dorsal root ganglion neurons, rat 
motor neurons and a human undifferentiated Schwann cell line. Systematic screening of serum reactivity against 
the two neuronal components of peripheral nerves, DRG and motor neurons, has never been performed before. 
In fact, our previous studies used hippocampal neurons, rat teased nerve fibers and rat brain sections to screen 
reactivity15,18. Therefore, although a partial sample overlap must be acknowledged, the different substrates used in 
our methods grant novelty and relevance to our results.
The search for diagnostic biomarkers in CIDP has been a research topic for decades2. Most patients with CIDP 
show an excellent response to PlEx and IVIg25,26. Response to IVIg follows time dynamics that strongly suggest direct 
competition of the therapeutic immunogloblulins with pathogenic autoantibodies27. The presence of IgG, IgM and 
complement deposits has been described in chronic inflammatory neuropathies for almost 40 years28 and confirm-
atory studies that passive transfer of IgG from CIDP patients led to demyelinating nerve pathology were performed 
Patient ID Motor neurons IgG Schwann cells IgG Schwann cells IgM Drg neurons IgG Drg neurons IgM PMP2ICC
12 0 0 0 2 0 0
18 0 0 0 1 2 ND
22 0 0 0 0 0 3
23 0 3 1 1 0 0
33 0 0 ND 3 ND 0
48 0 0 0 2 0 0
50 0 3 1 0 0 0
56 0 2 0 0 0 0
58 0 0 2 0 0 0
64 0 1 0 2 0 0
Table 2. CIDP patients with moderate to strong reactivity in ICC experiments.
Controls Patients P value
Schwann cells IgG ICC 0/28 (0%) 3/57 (5.3%) 0.5476
Schwann cells IgM ICC 0/28 (0%) 1/56 (1.8%) 1
DRG neurons IgG ICC 3/28 (10.7%) 4/57 (7.0%) 0.6793
DRG neurons IgM ICC 2/28 (7.1%) 1/56 (1.8%) 0.2565
Table 3. Statistical analysis of DRG neurons and Schwann cells ICC in CIDP patients and healthy controls. 
Moderate to strong fluorescence intensity scores, including scores two and three, and other stainings, featuring 
scores zero and one, from DRG neurons and Schwann cells IgG and IgM ICC experiments from patients 
and controls were analyzed using contingency analysis with the application of a two-tailed Fisher’s exact test, 
accepting an alpha-level <0.05 to determine significance.
www.nature.com/scientificreports/
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17 years ago29. However, the target antigens for most CIDP patients remain elusive. Considering the demyelinating 
nature of CIDP, the neuritogenic potential of myelin proteins and their discovery in some demyelinating hereditary 
neuropathies, myelin proteins were extensively studied as potential antigens in CIDP. MPZ, PMP2, PMP22 and 
connexin-31 among others were tested as possible candidate antigens, but clinically relevant autoantibodies could 
not be established5,7,10,30–32. We tried to replicate the results with two of those antigens (MPZ and PMP2) and found 
only one patient with antibodies against PMP2, both in serum and CSF, precluding further clinical correlations.
Gangliosides and ganglioside complexes are well-established targets of humoral responses and provide useful 
clinical-immunological correlations in diverse inflammatory neuropathies33. Considering this, anti-ganglioside anti-
bodies have also been studied in CIDP and other chronic inflammatory neuropathies34,35. Diverse CIDP-associated 
anti-ganglioside antibodies have been reported but, so far, antibodies targeting LM1-containing ganglioside com-
plexes are the only ones associated to specific clinical features such as ataxia12. Anti-ganglioside antibodies were 
systematically tested in our patients by ELISA and further confirmed with thin-layer chromatography (TLC). 
Four patients showed IgM antibodies against GM1. Two of them, who also had GD1b IgM antibodies, presented 
with the Lewis-Sumner variant of CIDP. Previous reports describing the clinical and immunological features of 
Lewis-Sumner did not find any association with GM1 antibodies or proposed them as a differential feature com-
pared to multifocal motor neuropathy (MMN)36,37. Description of clinical-immunological correlations in larger 
cohorts could clarify if there is a subset of CIDP patients with well-established anti-ganglioside antibody reactivities. 
Seven patients showed low anti-ganglioside/sulfatide antibody titers, probably without clinical relevance.
Our group and others have used candidate-antigen and unbiased approaches to study proteins of the node of 
Ranvier as potential targets of the immune response in CIDP13–15,17. Devaux’s and Yuki’s groups described anti-
bodies against nodal proteins in patients with CIDP and Guillain-Barré Syndrome (GBS), including IgG and IgM 
antibodies against neurofascin, gliomedin, CNTN-1 and NrCAM13. Later on, Meinl’s group described antibodies 
against neurofascin in very specific subsets of CIDP (and GBS) patients14. Our group published that a small subset 
of CIDP patients reacted strongly against neurons and that CNTN1 and the CNTN1/CASPR1 complex were the 
antigens in those patients15. Interestingly, these patients showed specific clinical features and poor response to 
IVIg, likely due to the IgG4 nature of the autoantibodies. We then described that some patients reacting against 
paranodal structures, harbored IgG4 anti-NF155 antibodies. These patients also showed poor response to IVIg 
and very specific clinical features18. Ever since, other groups have confirmed in independent cohorts the pres-
ence of anti-CNTN1 and anti-NF155 antibodies in very specific and infrequent CIDP19–22, and passive transfer 
of anti-CNTN1 IgG4 antibodies has demonstrated to be pathogenic24. The presence of antibodies against nodal 
neurofascins (NF140 and NF186) has been recently associated to specific clinical features, including an interest-
ing association with nephrotic syndrome16. However, other nodal antigens such as NrCAM or gliomedin have 
not been replicated yet. We tried to identify CIDP patients with antibodies against those nodal antigens and the 
CNTN2/CASPR2 complex and the two subunits of the nodal sodium channel but failed to identify any positive 
patients in contrast to previous studies. The low frequency of these antibodies may account for some of these 
disparities; larger cohorts in which systematic autoantibody screening is performed should be studied.
For seronegative CIDP patients we developed a screening approach to identify IgG and IgM antibodies using 
the three main cellular components of the peripheral nerve: motor neurons, DRG neurons and Schwann cells. A 
significant number of patients (22/57; 38.6%), showed reactivity against any of the three relevant cellular compo-
nents (a similar proportion to that found in other studies)13,38. Most of them showed exclusive reactivity against 
a single cell type, but a few reacted against two different cell types. Nine patients reacted strongly against DRG or 
Schwann cells and deserved inclusion in IP experiments. Presence of high concentrations of immunoglobulins 
in sera after IVIg treatment, might have contributed to unspecific staining, particularly of the IgG subtype, in 
our patients’ ICC experiments. In order to avoid this bias, as stated in the methods section, patients’ and controls’ 
ICC results were compared according to two separate categories: moderate to strong stainings, (including scores 
two and three respectively) and other stainings (including scores one and zero).The latter category being encom-
passed by negative samples (0) and samples with irrelevant background staining (1), including those that might 
have featured an unspecific staining as a consequence of higher immunoglobulin titers after IVIg treatment. Since 
only samples showing moderate or strong reactivities against peripheral nerve cells were used for IP experiments, 
IVIg treatment cannot be considered a confounding variable in our study. Frequencies of sera reacting against 
neural structures did not reach statistical significance, likely due to the small number of controls and to a rela-
tively high proportion of controls showing moderate unspecific staining, but it could be, as has been suggested for 
anti-ganglioside antibodies, that naturally occurring antibodies targeting nerve structures, are frequent in healthy 
population39. No relevant antigens were identified from the mass spectrometry analysis of the precipitated samples.
Finally we attempted whole nerve IP to discover antigens in typical CIDP patients and found two poten-
tial candidates: CD9, a tetraspanin present in the paranode40, and L1CAM, a protein of the neurofascin family. 
Unfortunately, we failed to confirm autoantibodies against these two antigens in CIDP. The group of Yuki also 
screened antibodies against CD9 and other tetraspanins and did not find such autoantibodies in CIDP either41.
Although the use of several antigens of murine origin (mammalian expression vectors encoding nodal pro-
teins and neuronal primary cultures) may be considered as a limitation of our study, their utility in previous 
works and in autoimmune encephalitis encouraged us to pursue novel antigen screening in murine models. 
Inter-species antigen variability, although minor in terms of sequence homology, may however be very relevant 
for autoantibody screening purposes. This happens with other nerve antigens such as myelin-associated glyco-
protein in polyneuropathy associated with monoclonal gammopathy or NF155 and should be taken into account 
in future studies. The use of human neural cells obtained from induced pluripotent stem cells could overcome 
these technical difficulties42. A very interesting study identified a subset of patients with inflammatory neuropa-
thies reacting against human Schwann cells and, thus, set the proof of principle that ICC over Schwann cells in 
isolation may also be useful for autoantibody screening purposes38. One important issue regarding our model is 
that it uses murine cells or undifferentiated human Schwann cells. The study by Kwa and coworkers used human 
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Schwann cells obtained from sural nerve biopsies and amputation material. The scarcity of this type of sample 
precludes routine use of these two cell sources. Exploring novel ways of obtaining differentiated human neural 
cells would therefore help refining these screening techniques.
Another limitation is that, although our screening approach is valid for any type of antigen, identification 
with IP and mass spectrometry is only useful for protein antigens and, thus, antigens of lipidic or glucidic nature 
cannot be identified. Finally, identification of relevant protein antigens with IP and mass spectrometry relies on 
completeness and accuracy of existing protein databases. Although murine and human protein databases cover a 
very significant proportion of the proteome, their completeness, accuracy and detail may be insufficient for novel 
antigens that may have not been studied in any other disease or model, and thus it is difficult to assign relevance 
to the identified antigens.
CIDP is defined based on broad clinical and electrophysiological criteria that successfully identify patients that 
may benefit from immunomodulatory therapy. However, the inclusion of patients with diverse clinical features 
into the same diagnostic category leads to clinical, electrophysiological, radiological and pathological heterogene-
ity that, in the end, interferes with translational research aimed to identify clinically meaningful biomarkers and, 
among them, autoantibodies. Our study provides the most comprehensive attempt to discover novel antigenic 
reactivities in CIDP and shows that the pattern of IgG and IgM reactivity of CIDP patients is heterogeneous and 
targets diverse nerve proteins and structures, further proving the difficulty in the identification of new biomarkers 
in this context. Our results may therefore help to understand the disparity in previous reports on autoantibodies 
in CIDP and supports the idea that larger CIDP registries that attempt to collect and homogenize clinical and 
biomarker information are very much needed.
Materials and Methods
Patients, informed consent and protocol approvals. Sixty-five consecutive patients fulfilling 
European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for 
CIDP and followed in Hospital de la Santa Creu i Sant Pau were included in this study. Twenty-eight healthy 
controls were additionally included in our experiments. Serum samples were obtained at inclusion in the study 
and stored at −80 °C until needed. Written informed consents were obtained from all subjects according to 
the Declaration of Helsinki. Participation in the study was conducted under a protocol approved by the Ethics 
Committee of the Hospital de la Santa Creu i Sant Pau. All experiments were performed in accordance with the 
relevant guidelines and regulations.
In regard to experiments involving rats, all experimental procedures were approved by our institution’s Service 
of Animal Experimentation at CSIC-ICCC (Institut Català de Ciències Cardiovasculars). All experiments were 
performed in accordance with due guidelines and regulations.
Protocol overview. The autoantibody screening in our patients was designed as a multi-step process 
(Supplementary Fig. S1). First, patients’ sera were tested for antibodies against gangliosides and against previously 
described antigens from myelin (MPZ, PMP2) or node of Ranvier; CNTN1, NF155, NrCAM, gliomedin, the 
CNTN1/CASPR1 and the CNTN2/CASPR2 complexes. Antibodies against the two subunits of the main sodium 
channel present at the node of Ranvier; NavB1 and NavB2 were also tested. Patients showing positivity towards 
CNTN1, CNTN1/CASPR1 or anti-NF155 (n = 8), all of them except two previously described elsewhere15,18,43, 
were excluded from statistical analysis in screening experiments, and were only used in such experiments as 
controls. These patients were neither tested in further IP analysis. Only patients harboring no reactivity against 
previously described antigens (n = 57) and healthy volunteers serving as negative controls (n = 28) were included 
in autoantibody screening experiments analysis.
Primary cultures of rat DRG and motor neurons, and a human, undifferentiated, Schwann cell line (ScienCell, 
CA, USA) were used to screen reactivity against peripheral nerve cells. Patients showing autoantibodies against 
any of these nerve structures were used for antigen discovery with immunoprecipitation. Sera of five typical CIDP 
cases were pooled and incubated in IP experiments with whole nerve lysate obtained from rat sciatic nerve and 
human cauda equina obtained from the IDIBAPS (Institut d’investigacions Biomèdiques August Pi i Sunyer) 
neural-tissue bank. Finally, if any candidate antigen was detected in any of the IP experiments, confirmatory 
experiments with transfected HEK cells encoding the protein of interest, followed.
Cell cultures. DRG and motor neurons were isolated and cultured following published protocols with 
minor modifications44,45. Briefly, DRG and spinal cords were dissected from E16 rat embryos and dissociated 
to a cell suspension in neurobasal medium (Gibco BRL, NY, USA) supplemented with B27 (Gibco BRL, NY, 
USA), Glutamax (Gibco BRL, NY, USA) and nerve growth factor (NGF) (Invitrogen, CA, USA). After 24 hours 
plated in glass-coverslips, cytosine arabinoside (ARA-C) (Sigma, MO, USA) and fluorouracil (5-FU) (Sigma MO, 
USA) were added to the medium to remove fibroblasts in DRG neurons cultures. In both cultures, medium was 
replaced every other day until reaching motor or DRG neuron full growth.
A commercial human Schwann cell line (ScienCell, CA, USA) was cultured following manufacturer’s instruc-
tions and plated onto glass coverslips until 70–80% confluence was reached.
DRG neuron, motor neuron and Schwann cell immunocytochemistry. Live DRG neurons, 
Schwann cells and motor neurons were incubated with patients’ sera diluted in culture medium. Cells were then 
fixed with 4% paraformaldehyde (Affymetrix Inc, CA, USA) and incubated with secondary goat anti-human 
IgG/IgM Alexa Fluor 488 antibody (both by Thermo Fisher Scientific, MA, USA). DRG neurons and Schwann 
cells were tested against IgG and IgM reactivities, both in patients and controls. Due to the limiting scarcity of 
rat motor neurons extraction, only patients were tested against IgG in these experiments. Finally, coverslips were 
mounted with Vectashield with DAPI (Vector Laboratories, CA, USA). Fluorescence signal intensity was scored 
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in a 0–3 scale by two independent researchers. Relevant images were obtained with the use of an Olympus BX51 
Fluorescence Microscope (Olympus Corporation, Japan) and processed with ImageJ (U. S. National Institutes of 
Health, MD, USA).
Immunoprecipitation. Sera showing moderate or strong reactivity against peripheral nerve cells were used 
for IP experiments using the same cell as IP substrate. Protein A and G agarose beads (Invitrogen, CA, USA) 
were used to isolate sera IgG bound overnight to the antigens in a cell culture extract. Precipitated proteins were 
detached from the agarose beads with Laemmli buffer (Bio-Rad, CA, USA) with 5% b-mercaptoethanol (Merck, 
Germany) and separated by electrophoresis. Bands appearing in patients’ IP but not in control’s were analyzed by 
mass spectrometry. Proteins were selected as candidate antigens when they fulfilled any of these criteria: protein 
score > 100, peptide sequence coverage >5% or two or more peptides identified with the absence of the same 
criteria in the control sample.
A subset of five patients with typical CIDP that did not react against nerve cells was used for IP experiments 
using rat whole nerve lysate or human cauda equina as the IP substrate following the exact same protocol to ana-
lyze precipitated proteins.
Anti-ganglioside antibody screening. Fifty-nine patients were screened for the presence of 
anti-ganglioside antibodies with our institution’s diagnostic protocol using ELISA46 as the general detection 
method and TLC47 for confirmatory experiments. Anti-ganglioside antibodies were considered positive at a 1:500 
titer. The remaining six CIDP patients in our cohort could not be analyzed due to sample scarcity.
HEK cell transfection and ICC. HEK293 cells were transfected with Lipofectamine 2000 (Invitrogen, CA, 
USA) with mammalian expression vectors encoding human MPZ, PMP2, gliomedin, CNTN1, CASPR1, CNTN2, 
CASPR2, NF155, CD9 and L1CAM, and murine NrCAM and NavB1 and NavB2. Cells were then fixed with 4% 
paraformaldehyde (Affymetrix Inc, CA, USA), permeabilized (if needed) with 0.3% TritonX-100 (Sigma, MO, 
USA) and blocked. ICC experiments were performed using patients’ sera and appropriate primary and secondary 
antibodies (Supplementary Table S3).
Statistical analysis. Fluorescence intensity scores from DRG neurons and Schwann cells IgG and IgM ICC 
experiments from patients and controls were analyzed by Stata v.13.1 (StataCorp LP, Texas, USA) using contin-
gency analysis with the application of a two-tailed Fisher’s exact test, accepting an alpha-level <0.05 to determine 
significance. Patients’ and controls’ ICC results in each condition were compared according to two separate cat-
egories: moderate to strong staining, including scores two and three, and other stainings. Scores two and three 
were considered positive, while score one was interpreted as unspecific background staining.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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